662 related articles for article (PubMed ID: 16010587)
1. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL; Disis ML
Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
[TBL] [Abstract][Full Text] [Related]
2. [Immunology of tuberculosis and cytokines].
Tsuyuguchi I
Kekkaku; 1995 May; 70(5):335-46. PubMed ID: 7783394
[TBL] [Abstract][Full Text] [Related]
3. [Tumor rejection antigen and cancer immunotherapy].
Matsutake T; Nakayama E
Gan To Kagaku Ryoho; 1995 Nov; 22(13):1871-7. PubMed ID: 7487115
[TBL] [Abstract][Full Text] [Related]
4. [The cell mediated immune response].
Haurum JS
Ugeskr Laeger; 1995 Jul; 157(27):3887-93. PubMed ID: 7645062
[TBL] [Abstract][Full Text] [Related]
5. Identification of promiscuous KIF20A long peptides bearing both CD4+ and CD8+ T-cell epitopes: KIF20A-specific CD4+ T-cell immunity in patients with malignant tumor.
Tomita Y; Yuno A; Tsukamoto H; Senju S; Kuroda Y; Hirayama M; Irie A; Kawahara K; Yatsuda J; Hamada A; Jono H; Yoshida K; Tsunoda T; Kohrogi H; Yoshitake Y; Nakamura Y; Shinohara M; Nishimura Y
Clin Cancer Res; 2013 Aug; 19(16):4508-20. PubMed ID: 23714729
[TBL] [Abstract][Full Text] [Related]
6. Role of interferons and other cytokines in the regulation of the immune response.
Belardelli F
APMIS; 1995 Mar; 103(3):161-79. PubMed ID: 7538771
[TBL] [Abstract][Full Text] [Related]
7. Augmenting T helper cell immunity in cancer.
Knutson KL; Disis ML
Curr Drug Targets Immune Endocr Metabol Disord; 2005 Dec; 5(4):365-71. PubMed ID: 16375690
[TBL] [Abstract][Full Text] [Related]
8. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
9. Specific and non-specific responses in host resistance to tumors.
Baldwin RW
Tokai J Exp Clin Med; 1983 Dec; 8(5-6):419-28. PubMed ID: 6398929
[TBL] [Abstract][Full Text] [Related]
10. [Identification of T cell epitopes from ovarian cancer associated anti-idiotype antibody].
Li W; Cui H; Chang XH; Cheng HY; Cheng YX; Feng J; Fu TY
Zhonghua Fu Chan Ke Za Zhi; 2008 Oct; 43(10):764-9. PubMed ID: 19087545
[TBL] [Abstract][Full Text] [Related]
11. New possibilities for cancer therapy with advances in cancer immunology.
MacLean GD; Longenecker BM
Can J Oncol; 1994 Apr; 4(2):249-54. PubMed ID: 7516257
[TBL] [Abstract][Full Text] [Related]
12. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination.
Kyte JA; Trachsel S; Risberg B; thor Straten P; Lislerud K; Gaudernack G
Cancer Immunol Immunother; 2009 Oct; 58(10):1609-26. PubMed ID: 19221745
[TBL] [Abstract][Full Text] [Related]
13. Multiple roles for CD4+ T cells in anti-tumor immune responses.
Kennedy R; Celis E
Immunol Rev; 2008 Apr; 222():129-44. PubMed ID: 18363998
[TBL] [Abstract][Full Text] [Related]
14. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
15. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications.
Becker Y
Anticancer Res; 2006; 26(2A):1113-34. PubMed ID: 16619514
[TBL] [Abstract][Full Text] [Related]
16. Differential antigen presentation in tumor immunity.
Schatten S; Drebin JA; Granstein RD; Greene MI
Fed Proc; 1984 Jun; 43(9):2460-4. PubMed ID: 6327399
[TBL] [Abstract][Full Text] [Related]
17. The critical role of type-1 innate and acquired immunity in tumor immunotherapy.
Ikeda H; Chamoto K; Tsuji T; Suzuki Y; Wakita D; Takeshima T; Nishimura T
Cancer Sci; 2004 Sep; 95(9):697-703. PubMed ID: 15471553
[TBL] [Abstract][Full Text] [Related]
18. [Tumor-specific immunotherapy: active immunotherapy by augmenting the induction of tumor-specific effector T cells through a T-T cell interaction mechanism].
Kosugi A; Fujiwara H; Hamaoka T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1527-35. PubMed ID: 6236750
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of T helper 1-biasing cytokine genes enhances the efficacy of gene gun immunization of mice: studies with the model tumor antigen beta-galactosidase and the BALB/c Meth A p53 tumor-specific antigen.
Tüting T; Gambotto A; Robbins PD; Storkus WJ; DeLeo AB
Gene Ther; 1999 Apr; 6(4):629-36. PubMed ID: 10476222
[TBL] [Abstract][Full Text] [Related]
20. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine.
Accolla RS; Ramia E; Tedeschi A; Forlani G
Front Immunol; 2019; 10():1806. PubMed ID: 31417570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
